$220,000 of GE HEALTHCARE TECHNOLOGIES INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"HR 1199/S 1544, Facilitating Innovative Nuclear Diagnostics Act of 2023, all provisions. S 866, American Innovation and Jobs Act, all provisions. HR 2673, American Innovation and R&D Competitiveness Act of 2023, all provisions. HR 3851/S 2464, Access to Breast Cancer Diagnosis Act of 2023, all provisions. HR 3086, Find It Early Act, all provisions. HR 1526/S 765, Reducing Hereditary Cancer Act, all provisions. HR 3305/S 1606, Black Maternal Health Momnibus Act, all provisions. HR 6395, Recognizing the Importance of Critical Minerals in Healthcare Act of 2023, all provisions. HR 8816, American Medical Innovation and Investment Act of 2024, all provisions. S 4638, National Defense Authorization Act for Fiscal Year 2025, provisions related to government contracting. Issues impacting artificial intelligence. Issues impacting corporate taxation. Issues impacting funding for health care including government research. Issues impacting health care and public health. Issues impacting manufacturing. Issues impacting medical device and health care cybersecurity. Issues impacting medical device regulation. Issues impacting medical insurance coverage. Issues impacting medical research. Issues impacting Medicare coverage and reimbursement for medical technology and health care services. Issues impacting servicing and repair of medical devices. Issues impacting wireless spectrum. Issues impacting international trade and supply chains. Issues impacting Veterans health."
You can find more data on corporate lobbying on Quiver Quantitative.
GEHC Insider Trading Activity
GEHC insiders have traded $GEHC stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $GEHC stock by insiders over the last 6 months:
- KENNETH R. STACHERSKI (Ch. Supply Chain & Serv. Ofc.) sold 19,008 shares for an estimated $1,581,845
- ROLAND ROTT (CEO, Imaging) sold 3,577 shares for an estimated $309,338
- THOMAS J. WESTRICK (CEO, Patient Care Solutions) sold 2,750 shares for an estimated $222,145
- PHILIP RACKLIFFE (CEO, AVS) sold 900 shares for an estimated $78,867
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GEHC Hedge Fund Activity
We have seen 587 institutional investors add shares of GEHC stock to their portfolio, and 509 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GENERAL ELECTRIC CO removed 17,250,000 shares (-56.5%) from their portfolio in Q3 2024, for an estimated $1,618,912,500
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 5,092,040 shares (-63.1%) from their portfolio in Q3 2024, for an estimated $477,887,954
- CAPITAL RESEARCH GLOBAL INVESTORS added 4,077,152 shares (+7.5%) to their portfolio in Q3 2024, for an estimated $382,640,715
- CITADEL ADVISORS LLC added 3,546,548 shares (+10431023.5%) to their portfolio in Q3 2024, for an estimated $332,843,529
- D1 CAPITAL PARTNERS L.P. added 2,857,314 shares (+inf%) to their portfolio in Q3 2024, for an estimated $268,158,918
- BLACKROCK, INC. added 2,384,145 shares (+7.0%) to their portfolio in Q3 2024, for an estimated $223,752,008
- JANE STREET GROUP, LLC added 2,370,035 shares (+1516.2%) to their portfolio in Q3 2024, for an estimated $222,427,784
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
